- Home
- SPFI vs AVTX Comparison
SPFI vs AVTX Comparison
Compare SPFI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | AVTX |
|---|---|---|
| Founded | 1941 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 847.8M | 982.5M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPFI | AVTX |
|---|---|---|
| Price | $44.16 | $19.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $46.00 | $40.57 |
| AVG Volume (30 Days) | 102.3K | ★ 729.8K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | 17.81 | ★ 72.07 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | N/A |
| P/E Ratio | $24.31 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $35.34 | $8.65 |
| 52 Week High | $46.94 | $24.27 |
Technical Indicators
Market Signals| Indicator | SPFI | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 55.53 |
| Support Level | $44.05 | $17.40 |
| Resistance Level | $45.40 | $20.68 |
| Average True Range (ATR) | 0.79 | 1.06 |
| MACD | -0.21 | 0.04 |
| Stochastic Oscillator | 41.61 | 66.12 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.